- Home
- TVA vs ALEC Comparison
TVA vs ALEC Comparison
Compare TVA & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
HOLD
Current Price
$1.82
Company Overview
Basic Information| Metric | TVA | ALEC |
|---|---|---|
| Founded | 2024 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.2M | 275.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TVA | ALEC |
|---|---|---|
| Price | $10.64 | $1.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 145.1K | ★ 4.0M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $214.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.28 | $1.09 |
| 52 Week High | $11.44 | $2.76 |
Technical Indicators
Market Signals| Indicator | TVA | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 68.76 | 44.01 |
| Support Level | $10.47 | $1.43 |
| Resistance Level | $10.74 | $2.65 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 84.21 | 10.00 |
Price Performance
Historical Comparison TVA
ALEC
About TVA Texas Ventures Acquisition III Corp Class A Ordinary Share
Texas Ventures Acquisition III Corp is a blank check company.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.